TomoTherapy® in Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is highly prevalent in southeast of Asia, and it is predominantly treated by radiotherapy (RT). Intensity-modulated RT (IMRT) exhibits better dosimetric advantages over two-dimensional RT (2D-RT) or three-dimensional conformal RT (3D-CRT). It has significantly improved the local control rate of NPC and reduced acute and chronic toxicities. Helical TomoTherapy® was an emerging technology that integrates IMRT, image-guided intensity modulated radiotherapy (IGRT) and dose-guided intensity modulated radiotherapy (DGRT). TomoTherapy makes a perfect combination of linear accelerator and helical CT, breaking through many limitations of traditional accelerator. While rotating the irradiation target area, the treatment couch advances axially through the center of the stand, which is used to treat tumors efficiently and accurately. This webinar will focus on the treatment of NPC by TomoTherapy. Firstly, describing the therapeutic mechanism of TomoTherapy, the advantages and limitations of TomoTherapy in the treatment of tumors. This webinar will explain how to implement TomoTherapy in a patient with NPC. Finally, the experience of treating NPC by TomoTherapy in the Sun Yat-sen University Cancer Center, Guangzhou, China will be shared.

Advances in TomoTherapy®/Radixact® Treatment and QA – Guidelines from TG-306

Since the publication of Task Group 148 in 2010, the TomoTherapy platform has undergone substantial development involving treatment delivery, image guidance, motion management, and treatment planning systems (TPS). New hardware and software capabilities have dramatically changed its delivery and planning characteristics. Task Group 306 was formed to provide guidance on the implementation, management, and quality assurance for these technological advances. In this session, the work of Task Group 306 will be presented. Changes to the TomoTherapy platform since 2010 and the impact on clinical delivery and QA practices, including QA tests and tolerance limits will be presented.

MyAccuray: Accuray Synchrony® Raises the Bar in AAPM MArkerless Lung Target Tracking Challenge

Delivering effective and safe lung cancer stereotactic body radiation therapy (SBRT) requires technology that can account for lung tumor motion. Both fiducial-based and markerless tracking algorithms currently exist, with markerless being a focus of innovation, investment and research in the field. These tracking algorithms, however, have not been benchmarked using a common, prospective measurement methodology. The American Association of Physicists in Medicine (AAPM) designed the MArkerless Lung Target Tracking CHallenge (MATCH), an AAPM Grand Challenge, to compare the precision and accuracy of existing markerless tracking algorithms.

TomoTherapy® for Breast Cancer in a Clinical Practice

In this webinar we will present both clinical and technical aspects of our hypofractationed approach to whole breast, partial breast and breast reirradation using TomoTherapy®. We will describe how we select patient for TomoDirect™ and TomoHelical™ modalities, and will share details of our Phase I/II clinical trial on single fraction ablative preoperative radiation treatment for early-stage breast cancer.

Russian Experience of using Helical TomoTherapy for Total Body Irradiation in Wide Heterogenic Cohort of 262 Pediatric Patients with Hematological Malignancies

Dmitry Rogachev National Research Center in Russia is a leading specialized center in the area of pediatric hematology/oncology and immunology. In this webinar we will share our experience with Helical TomoTherapy for the application of Total Body Irradiation in a wide heterogenic cohort of pediatric patients with hematological malignancies. We have treated 262 pediatric patients since this approach was introduced in our center in 2014.